Financhill
Sell
31

KROS Quote, Financials, Valuation and Earnings

Last price:
$14.59
Seasonality move :
-5.28%
Day range:
$14.01 - $14.74
52-week range:
$9.12 - $72.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.63x
P/B ratio:
0.81x
Volume:
581.5K
Avg. volume:
968.1K
1-year change:
-70.36%
Market cap:
$591.8M
Revenue:
$3.6M
EPS (TTM):
-$0.18

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
KROS
Keros Therapeutics
$56.6M $0.01 10251.84% -9.73% $32.20
ALT
Altimmune
$560 -$0.34 -87.6% -15.83% $20.56
MRK
Merck &
$15.3B $2.14 -1.55% -4.04% $101.91
REGN
Regeneron Pharmaceuticals
$3.2B $8.48 -7.35% -30.58% $797.21
VKTX
Viking Therapeutics
-- -$0.31 -- -120.34% $90.26
VSTM
Verastem
$100K -$0.78 -39.89% -100% $15.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
KROS
Keros Therapeutics
$14.57 $32.20 $591.8M -- $0.00 0% 2.63x
ALT
Altimmune
$5.71 $20.56 $463.1M -- $0.00 0% 20,612.30x
MRK
Merck &
$77.58 $101.91 $194.8B 11.29x $0.81 4.07% 3.08x
REGN
Regeneron Pharmaceuticals
$588.34 $797.21 $63.5B 14.98x $0.88 0.3% 4.77x
VKTX
Viking Therapeutics
$26.98 $90.26 $3B -- $0.00 0% --
VSTM
Verastem
$8.31 $15.75 $456.6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
KROS
Keros Therapeutics
-- 1.088 -- 18.79x
ALT
Altimmune
-- 2.792 -- 15.54x
MRK
Merck &
41.89% 0.358 16.34% 0.80x
REGN
Regeneron Pharmaceuticals
6.33% 0.973 2.89% 3.90x
VKTX
Viking Therapeutics
-- -0.956 -- --
VSTM
Verastem
50.52% -1.377 40.34% 3.10x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
KROS
Keros Therapeutics
-- $152M 0.78% 0.78% 71.97% $160.6M
ALT
Altimmune
-- -$21.8M -62.28% -62.28% -405100% -$16.8M
MRK
Merck &
$12.1B $5.9B 21.5% 39.02% 40.03% $1.2B
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M
VKTX
Viking Therapeutics
-- -$55.5M -- -- -- -$31.2M
VSTM
Verastem
-- -$44.2M -78.01% -120.71% -71.18% -$38.7M

Keros Therapeutics vs. Competitors

  • Which has Higher Returns KROS or ALT?

    Altimmune has a net margin of 70.27% compared to Keros Therapeutics's net margin of -391500%. Keros Therapeutics's return on equity of 0.78% beat Altimmune's return on equity of -62.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    KROS
    Keros Therapeutics
    -- $3.62 $728.9M
    ALT
    Altimmune
    -- -$0.26 $142.2M
  • What do Analysts Say About KROS or ALT?

    Keros Therapeutics has a consensus price target of $32.20, signalling upside risk potential of 110.71%. On the other hand Altimmune has an analysts' consensus of $20.56 which suggests that it could grow by 259.99%. Given that Altimmune has higher upside potential than Keros Therapeutics, analysts believe Altimmune is more attractive than Keros Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    KROS
    Keros Therapeutics
    6 5 0
    ALT
    Altimmune
    5 1 0
  • Is KROS or ALT More Risky?

    Keros Therapeutics has a beta of 1.321, which suggesting that the stock is 32.134% more volatile than S&P 500. In comparison Altimmune has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.05%.

  • Which is a Better Dividend Stock KROS or ALT?

    Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KROS or ALT?

    Keros Therapeutics quarterly revenues are $211.2M, which are larger than Altimmune quarterly revenues of $5K. Keros Therapeutics's net income of $148.5M is higher than Altimmune's net income of -$19.6M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.63x versus 20,612.30x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KROS
    Keros Therapeutics
    2.63x -- $211.2M $148.5M
    ALT
    Altimmune
    20,612.30x -- $5K -$19.6M
  • Which has Higher Returns KROS or MRK?

    Merck & has a net margin of 70.27% compared to Keros Therapeutics's net margin of 32.71%. Keros Therapeutics's return on equity of 0.78% beat Merck &'s return on equity of 39.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    KROS
    Keros Therapeutics
    -- $3.62 $728.9M
    MRK
    Merck &
    77.98% $2.01 $83.2B
  • What do Analysts Say About KROS or MRK?

    Keros Therapeutics has a consensus price target of $32.20, signalling upside risk potential of 110.71%. On the other hand Merck & has an analysts' consensus of $101.91 which suggests that it could grow by 31.36%. Given that Keros Therapeutics has higher upside potential than Merck &, analysts believe Keros Therapeutics is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    KROS
    Keros Therapeutics
    6 5 0
    MRK
    Merck &
    12 11 0
  • Is KROS or MRK More Risky?

    Keros Therapeutics has a beta of 1.321, which suggesting that the stock is 32.134% more volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

  • Which is a Better Dividend Stock KROS or MRK?

    Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.07% to investors and pays a quarterly dividend of $0.81 per share. Keros Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios KROS or MRK?

    Keros Therapeutics quarterly revenues are $211.2M, which are smaller than Merck & quarterly revenues of $15.5B. Keros Therapeutics's net income of $148.5M is lower than Merck &'s net income of $5.1B. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.63x versus 3.08x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KROS
    Keros Therapeutics
    2.63x -- $211.2M $148.5M
    MRK
    Merck &
    3.08x 11.29x $15.5B $5.1B
  • Which has Higher Returns KROS or REGN?

    Regeneron Pharmaceuticals has a net margin of 70.27% compared to Keros Therapeutics's net margin of 26.7%. Keros Therapeutics's return on equity of 0.78% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    KROS
    Keros Therapeutics
    -- $3.62 $728.9M
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About KROS or REGN?

    Keros Therapeutics has a consensus price target of $32.20, signalling upside risk potential of 110.71%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $797.21 which suggests that it could grow by 35.5%. Given that Keros Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Keros Therapeutics is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    KROS
    Keros Therapeutics
    6 5 0
    REGN
    Regeneron Pharmaceuticals
    14 4 0
  • Is KROS or REGN More Risky?

    Keros Therapeutics has a beta of 1.321, which suggesting that the stock is 32.134% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

  • Which is a Better Dividend Stock KROS or REGN?

    Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.3% to investors and pays a quarterly dividend of $0.88 per share. Keros Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KROS or REGN?

    Keros Therapeutics quarterly revenues are $211.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Keros Therapeutics's net income of $148.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.63x versus 4.77x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KROS
    Keros Therapeutics
    2.63x -- $211.2M $148.5M
    REGN
    Regeneron Pharmaceuticals
    4.77x 14.98x $3B $808.7M
  • Which has Higher Returns KROS or VKTX?

    Viking Therapeutics has a net margin of 70.27% compared to Keros Therapeutics's net margin of --. Keros Therapeutics's return on equity of 0.78% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    KROS
    Keros Therapeutics
    -- $3.62 $728.9M
    VKTX
    Viking Therapeutics
    -- -$0.41 --
  • What do Analysts Say About KROS or VKTX?

    Keros Therapeutics has a consensus price target of $32.20, signalling upside risk potential of 110.71%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 234.56%. Given that Viking Therapeutics has higher upside potential than Keros Therapeutics, analysts believe Viking Therapeutics is more attractive than Keros Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    KROS
    Keros Therapeutics
    6 5 0
    VKTX
    Viking Therapeutics
    10 2 0
  • Is KROS or VKTX More Risky?

    Keros Therapeutics has a beta of 1.321, which suggesting that the stock is 32.134% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

  • Which is a Better Dividend Stock KROS or VKTX?

    Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KROS or VKTX?

    Keros Therapeutics quarterly revenues are $211.2M, which are larger than Viking Therapeutics quarterly revenues of --. Keros Therapeutics's net income of $148.5M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.63x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KROS
    Keros Therapeutics
    2.63x -- $211.2M $148.5M
    VKTX
    Viking Therapeutics
    -- -- -- -$45.6M
  • Which has Higher Returns KROS or VSTM?

    Verastem has a net margin of 70.27% compared to Keros Therapeutics's net margin of -82.56%. Keros Therapeutics's return on equity of 0.78% beat Verastem's return on equity of -120.71%.

    Company Gross Margin Earnings Per Share Invested Capital
    KROS
    Keros Therapeutics
    -- $3.62 $728.9M
    VSTM
    Verastem
    -- -$0.96 $80.9M
  • What do Analysts Say About KROS or VSTM?

    Keros Therapeutics has a consensus price target of $32.20, signalling upside risk potential of 110.71%. On the other hand Verastem has an analysts' consensus of $15.75 which suggests that it could grow by 89.53%. Given that Keros Therapeutics has higher upside potential than Verastem, analysts believe Keros Therapeutics is more attractive than Verastem.

    Company Buy Ratings Hold Ratings Sell Ratings
    KROS
    Keros Therapeutics
    6 5 0
    VSTM
    Verastem
    7 0 0
  • Is KROS or VSTM More Risky?

    Keros Therapeutics has a beta of 1.321, which suggesting that the stock is 32.134% more volatile than S&P 500. In comparison Verastem has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.503%.

  • Which is a Better Dividend Stock KROS or VSTM?

    Keros Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KROS or VSTM?

    Keros Therapeutics quarterly revenues are $211.2M, which are larger than Verastem quarterly revenues of $10M. Keros Therapeutics's net income of $148.5M is higher than Verastem's net income of -$52.1M. Notably, Keros Therapeutics's price-to-earnings ratio is -- while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics is 2.63x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KROS
    Keros Therapeutics
    2.63x -- $211.2M $148.5M
    VSTM
    Verastem
    -- -- $10M -$52.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will DigitalOcean Stock Bounce Back?
Will DigitalOcean Stock Bounce Back?

DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock